Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(15;17)(q22;q21) in treatment related leukemia

Written2003-10Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)


ICD-Morpho 9920/3 Therapy-related myeloid neoplasms
Atlas_Id 1298
Note This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.
  t(15;17)(q22;q21) Left: G-banding - Courtesy Roland Berger (top 2), and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services (bottom 2); center and right: R- banding and FISH - Courtesy Hossein Mossafa.

Clinics and Pathology

Disease Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML)
Note The study included 41 cases; t-MDS with progression to AML accounted for 7% and t-AML for the remaining 93% the AML subtype was M3 in all but one case; no case of acute lymphoblastic leukaemia
Epidemiology t(15;17)(q22;q21) was found in 8% of t-MDS/t-AML; sex ratio: 15M/26F
Clinics Age at diagnosis of the primary disease 46 yrs (range 18-79); age at diagnosis of the t-MDS/t-AML: 49 yrs (range 19-81). Median interval was 29 mths (range: 9-175). Primary disease was a solid tumor in 71% of cases ( breast cancer in particular) and a hematologic malignancy in 27%, treatment was radiotherapy (29%, a high proportion compared to other groups), chemotherapy (17%), or both (54%). Treatment included topoisomerase II inhibitors in 49% of cases and alkylating agents in 59%.
Prognosis Median survival was 29 mths. Outcome was better than the outcome of patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a 21q22 rearangement) and similar, during the first 2 yrs to that of the inv(16) treatment related leukemias.


Additional anomalies The t(15;17) was found solely in 59% of cases; additional anomalies were: +8 in 12% , -5/del(5q) in 5%, or -7/del(7q).

Result of the chromosomal anomaly

Hybrid gene
Description 5' PML -3' RARA


Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J
Genes, chromosomes & cancer. 2002 ; 33 (4) : 395-400.
PMID 11921273


This paper should be referenced as such :
Huret, JL
t(15;17)(q22;q21) in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2004;8(1):27-28.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Translocations implicated (Data extracted from papers in the Atlas)

 t(15;17)(q22;q21) in treatment related leukemia

External links

Mitelman databaset(15;17)(q22;q21)
arrayMap (UZH-SIB Zurich)Topo ( C42) Morph ( 9920/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 16:37:29 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us